
Culp Announces Fourth Quarter and Full Year Fiscal 2025 Results, Completed Restructuring Provides Foundation for Improved Operating Performance in Fiscal 2026
HIGH POINT, N.C.--(BUSINESS WIRE)--Culp, Inc. (NYSE: CULP), a leading provider of fabrics for bedding and upholstery fabrics for residential and commercial furniture, today reported financial and operating results for the fourth quarter and fiscal year ended April 27, 2025.
Iv Culp, President and Chief Executive Officer, commented, 'Fiscal 2025 was a year of heavy lifting across CULP, and we are encouraged by the results of our work to transform our cost structure and better position the company for growth. Given the challenging revenue environment and tariff-related uncertainty that is evident and continues across the industry, we concentrated on what we can control and successfully executed on a variety of aggressive initiatives that should drive better operating leverage, particularly as market conditions improve. We also continued to play to our strength in providing the highest levels of service, product offerings and supply chain optionality to our customers, and we believe that our market share remains strong and continues to expand within certain targeted segments.
'The recent sale of our manufacturing facility in Canada capped the completion of the restructuring plan we announced last year including facility closures and consolidations in our mattress fabrics division, as well as a transition to an asset-light, strategic sourcing model for certain major product lines. We are pleased to see the benefits of that plan reflected in our financial results, with a lower fixed cost base and increased efficiencies in our mattress fabrics division helping to drive improvement during the year and significantly better overall operating results for the quarter despite the pressured macro conditions.
'In light of the continuing market softness, along with heightened tariff uncertainty, we are taking additional action including the integration of our two operating divisions, Culp Upholstery Fabrics and Culp Home Fashions, into a unified CULP-branded business that enhances our ability to anticipate and react to market trends as well as optimize resources across our organization. We expect this more centralized approach to improve scale efficiencies throughout CULP and to generate additional savings as we progress through fiscal 2026. In addition, the related facility consolidation activity should elevate the operating profile of our upholstery fabrics business, which continues to achieve profitability in the face of historically low demand for home furnishings and challenges from high tariff rates on China-produced goods. We also recently extended our credit facility with Wells Fargo for an additional three years, which we believe will provide us with additional flexibility and liquidity as needed to fund and grow our business going forward.
Mr. Culp concluded, 'I remain incredibly proud of our team's ability to respond to the changing needs of our business. Thanks to their hard work and dedication, we move into our new fiscal year with a leaner, more flexible global platform enabling us to quickly respond to market and tariff fluidity, as well as a highly resilient business model well-positioned to seize opportunities and meet the challenges ahead."
Fiscal 2025 Fourth Quarter Financial Highlights
Consolidated net sales of $48.8 million, generally flat to prior-year period net sales of $49.5 million, with mattress fabric sales up 5.3 percent and upholstery fabric sales down 8.9 percent year-over-year.
GAAP consolidated loss from operations of $(2.2) million (including $1.5 million in restructuring and related expenses), compared with GAAP consolidated loss from operations of $(4.2) million (including $204,000 in restructuring expense during the period).
- Non-GAAP operating loss of $(704) thousand, a marked improvement over the prior-year period's non-GAAP operating loss of $(4.0) million (see reconciliation table on page 16) driven primarily by cost and efficiency benefits from the restructuring plan and also favorably impacted by lower inventory markdowns.
- Continued momentum in mattress fabrics operating performance, including significant improvement in operating loss from the prior-year period and consistent improvement throughout the year.
- Continued profitability in the upholstery fabrics segment despite a low-revenue industry environment and tariff-related challenges.
Net loss of $(2.1) million (including $1.5 million in restructuring and related expenses), or $(.17) per diluted share, compared to a net loss of $(4.9) million, or $(.39) per diluted share, in the prior-year period.
- Adjusted EBITDA for the period was $559 thousand, compared to negative $(2.2) million in the prior-year period (see reconciliation table on page 20), with the improvement driven primarily by restructuring activities and also favorably impacted by lower inventory markdowns.
Fiscal 2025 Full Year Financial Highlights
Consolidated net sales of $213.2 million, down 5.4 percent from the prior year, with mattress fabric sales down 2.1 percent and upholstery fabric sales down 8.8 percent.
GAAP consolidated loss from operations of $(18.4) million (including $9.4 million in restructuring and related expenses), compared with GAAP consolidated loss from operations of $(11.3) million (including $676,000 in restructuring and related expenses during the period).
- Non-GAAP operating loss of $(9.0) million, an improvement over the prior-year period's non-GAAP operating loss of $(10.6) million (see reconciliation table on page 17) driven primarily by the same dynamics driving the improvement in non-GAAP operating loss during the fourth quarter.
Net loss of $(19.1) million (including $9.4 million in restructuring and related expenses), or $(1.53) per diluted share, compared with a net loss of $(13.8) million, or $(1.11) per diluted share, for the prior year.
As of April 27, 2025, the Company maintained $5.6 million in total cash and $12.7 million in outstanding debt under its credit facilities.
Restructuring Plan Update
The restructuring plan announced in May of 2024, which was primarily focused within the Company's mattress fabrics business, was completed as planned, with the sale of the Company's manufacturing facility in Quebec, Canada, consummated on April 30, 2025. The Company continues to expect the restructuring plan to generate $10.0-$11.0 million in annualized savings and operating improvements, with many of these benefits already beginning to manifest in the Company's fourth quarter fiscal 2025 results.
The Company incurred total restructuring and restructuring-related expenses of $9.4 million in fiscal 2025, of which $5.6 million consisted of cash expenditures. The Company funded close to $2.3 million of these cash expenditures with proceeds from the sale of excess manufacturing equipment, proceeds from a building lease termination in Haiti, and a small portion of the proceeds from the sale of its Canada facility. In fiscal 2026, the Company expects to realize a total of approximately $3.0 to $3.5 million in cash proceeds, net of all taxes and commissions, on the sale of its Canada facility.
Business Segment Highlights
Mattress Fabrics Segment
Sales for this segment were $27.1 million for the fourth quarter, up 5.3 percent compared with sales of $25.8 million in the prior-year period. Sales continued to be pressured by industry-wide low demand and related challenges from weaker consumer spending and housing market trends, but the Company continues to win new business with larger customers.
Operating loss was $(217) thousand for the fourth quarter, compared to an operating loss of $(2.9) million in the prior-year period, with the improvement driven primarily by higher gross margins attributable to lower fixed costs and operating efficiency improvements derived from the restructuring plan and lower inventory markdowns.
For the full year, sales were $113.9 million, down 2.1 percent compared with sales of $116.4 million for fiscal 2024, with the decrease driven by the above-referenced weak industry conditions and related macro-economic challenges.
For the full year, operating loss was $(5.2) million, compared with an operating loss of ($6.8) million for fiscal 2024. Operating performance continued to be pressured by lower sales, but improved consistently during the year, with the improvement driven primarily by the same dynamics impacting the segment's operating performance for the fourth quarter.
Upholstery Fabrics Segment
Sales for this segment were $21.7 million for the fourth quarter, down 8.9 percent compared with sales of $23.8 million in the prior-year period. The year-over-year decline was driven primarily by continued softness in the home furnishings market and lower comparable sales to a large residential fabric customer that uniquely concentrated more of its annual purchasing in the first half of fiscal 2025 and strategically managed inventory levels in the back half of the year. The market uncertainty from the recent tariff-related actions and the timing of the Chinese New Year holiday (which predominantly affected only the fourth quarter rather than multiple periods) also contributed to lower sales. However, demand with hospitality/contract customers remained relatively solid during the quarter, with sales in that market accounting for approximately 42.0 percent of the segment's total sales.
Operating income was $1.1 million for the fourth quarter, compared with operating income of $975 thousand in the prior-year period. Operating performance continued to be pressured by lower sales, but that pressure was partially offset by lower inventory markdowns, a more favorable mix of higher-margin hospitality/contract sales, and lower SG&A expenses.
For the full year, sales were $99.3 million, down 8.8 percent compared with sales of $109.0 million for fiscal 2024, with the decrease primarily reflecting the ongoing demand deterioration in the home furnishings industry due to what remains a challenging macro-economic environment.
For the full year, operating income was $4.1 million, compared to operating income of $5.8 million for fiscal 2024, with the decline driven primarily by lower sales partially offset by lower inventory markdowns and lower SG&A expenses.
Balance Sheet, Cash Flow, and Liquidity
As of April 27, 2025, the Company maintained $5.6 million in total cash and $12.7 million in outstanding debt under its credit facilities, of which $2.8 million constituted supplier financing. The outstanding debt was primarily incurred for restructuring activities and to fund worldwide working capital.
As of April 27, 2025, the Company maintained approximately $27.0 million in liquidity consisting of $5.6 million in cash and $21.4 million in borrowing availability under its domestic credit facility. On June 12, 2025, the Company extended the term of its domestic credit facility with Wells Fargo Bank for an additional three years and amended it in certain other respects. Subject to borrowing base limitations, this credit facility allows the Company to borrow up to $30 million and contains an accordion feature that could increase that amount by an additional $10 million based on mutual agreement.
Cash flow from operations and free cash flow were negative $(17.7) million and negative $(17.1) million, respectively, for fiscal 2025 (see reconciliation table on page 13), with both primarily affected by operating losses, including $5.6 million in non-recurring cash restructuring charges, and, with respect to free cash flow, planned strategic investments in capital expenditures mostly related to the mattress fabrics segment as we focused on restructuring that business.
Capital expenditures for fiscal 2025 were $2.9 million, down from $3.7 million for fiscal 2024 due to an effort to strategically manage capital and focus on projects targeting operating efficiency and future growth.
Financial Outlook
Due to macro-economic uncertainty and the fluid tariff environment, the Company is not providing specific financial guidance, but only limited annual guidance at this time.
The Company anticipates year-over-year sales growth in its mattress fabrics business and for the sales pressure on the residential side of its upholstery business to continue.
The cost and efficiency benefits of the recently completed restructuring plan are expected to continue to drive meaningful operating improvement as the year progresses, particularly as the Company moves beyond the tariff-related sales and margin pressure impacting the first quarter. In addition, the fiscal 2026 division integration initiative and related facility consolidation activity, along with tariff-related price increases, should further bolster operating performance, particularly as the Company progresses beyond the first quarter.
While the Company intends to continue utilizing borrowings as necessary under its domestic and foreign credit facilities during fiscal 2026 in connection with funding working capital needs and growth, integration and efficiency initiatives, it will continue to aggressively manage liquidity and capital expenditures and prioritize free cash flow.
The Company's expectations are based on information available at the time of this press release and reflect certain assumptions by management regarding the Company's business and industry trends, the projected impact of restructuring and integration initiatives, and ongoing tariff and market headwinds. The Company's expectations also assume no further meaningful impacts from tariffs and trade negotiations.
Conference Call
Culp, Inc. will hold a conference call to discuss financial results for the fourth quarter and full fiscal year 2025 on Thursday, June 26, 2025, at 9:00 a.m. Eastern Time. A live webcast of this call can be accessed on the 'Upcoming Events' section on the 'Investor Relations' page of the Company's website, www.culp.com. A replay of the webcast will be available for 30 days under the 'Past Events' section on the 'Investor Relations' page of the Company's website.
About the Company
Culp, Inc. is one of the largest marketers of mattress fabrics for bedding and upholstery fabrics for residential and commercial furniture in North America. The Company markets a variety of fabrics to its global customer base of leading bedding and furniture companies, including fabrics produced at Culp's manufacturing facilities and fabrics sourced through other suppliers. Culp has manufacturing and sourcing capabilities located in the United States, China, Haiti, Turkey, and Vietnam.
Forward Looking Statements
This release contains 'forward-looking statements' within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934). Such statements are inherently subject to risks and uncertainties that may cause actual events and results to differ materially from such statements. Forward-looking statements are statements that include projections, expectations, or beliefs about future events or results or otherwise are not statements of historical fact. Such statements are often but not always characterized by qualifying words such as 'expect,' 'believe,' 'will,' 'may,' 'should,' 'could,' 'potential,' 'continue,' 'target,' 'predict', 'seek,' 'anticipate,' 'estimate,' 'intend,' 'plan,' 'project,' and their derivatives, and include but are not limited to statements about expectations, projections, or trends for our future operations, strategic initiatives and plans, restructuring and integration actions, production levels, new product launches, sales, profit margins, profitability, operating (loss) income, capital expenditures, working capital levels, cost savings (including, without limitation, anticipated cost savings from restructuring and integration actions), income taxes, SG&A or other expenses, pre-tax (loss) income, earnings, cash flow, and other performance or liquidity measures, as well as any statements regarding dividends, share repurchases, liquidity, use of cash and cash requirements, ending cash balances and cash positions, borrowing capacity, investments, potential acquisitions, cash and non-cash restructuring and restructuring-related charges, expenses, and/or credits, net proceeds from restructuring related asset dispositions, future economic or industry trends, public health epidemics, or future developments. There can be no assurance that we will realize these expectations or meet our guidance, or that these beliefs will prove correct.
Factors that could influence the matters discussed in such statements include the level of housing starts and sales of existing homes, demand for home furnishings products, consumer confidence, trends in disposable income, and general economic conditions. Decreases in these economic indicators could have a negative effect on our business and prospects. Likewise, increases in interest rates, particularly home mortgage rates, and increases in consumer debt or the general rate of inflation, could affect us adversely. The future performance of our business depends in part on our success in conducting and finalizing acquisition negotiations and integrating acquired businesses into our existing operations. Changes in consumer tastes or preferences toward products not produced by us could erode demand for our products. Changes in tariffs or trade policy, including changes in U.S. trade enforcement priorities, or changes in the value of the U.S. dollar versus other currencies, could affect our financial results because a significant portion of our operations are located outside the United States. Strengthening of the U.S. dollar against other currencies could make our products less competitive on the basis of price in markets outside the United States, and strengthening of currency in China can have a negative impact on our sales of products produced there. In addition, because our foreign operations use the U.S. dollar as their functional currency, changes in the exchange rate between the local currency of those operations and the U.S dollar can affect our reported profits from those foreign operations. Also, economic or political instability in international areas could affect our operations or sources of goods in those areas, as well as demand for our products in international markets. The impact of public health epidemics on employees, customers, suppliers, and the global economy, such as the coronavirus pandemic, could also adversely affect our operations and financial performance. In addition, the impact of potential asset impairments, including impairments of property, plant, and equipment, inventory, or intangible assets, as well as the impact of valuation allowances applied against our net deferred income tax assets, could affect our financial results. Increases in freight costs, labor costs, and raw material prices, including increases in market prices for petrochemical products, can also significantly affect the prices we pay for shipping, labor, and raw materials, respectively, and in turn, increase our operating costs and decrease our profitability. Also, our success in diversifying our supply chain with reliable partners to effectively service our global platform could affect our operations and adversely affect our financial results. Finally, the future performance of our business also depends on our ability to successfully restructure our mattress fabric operations and return the segment to profitability as well as successfully integrate our mattress fabrics and upholstery fabrics segments and realize the expected benefits of that integration effort, which may not meet our expectations. Further information about these factors, as well as other factors that could affect our future operations or financial results and the matters discussed in forward-looking statements, is included in Item 1A 'Risk Factors' in our most recent Form 10-K and Form 10-Q reports filed with the Securities and Exchange Commission.
Many of these factors are macroeconomic in nature and are, therefore, beyond our control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from those described in this release as anticipated, believed, estimated, expected, intended, planned or projected. The forward-looking statements included in this release are made only as of the date of this report. Unless required by United States federal securities laws, we neither intend nor assume any obligation to update these forward-looking statements for any reason after the date of this release to conform these statements to actual results or to changes in our expectations. A forward-looking statement is neither a prediction nor a guarantee of future events or circumstances, and those future events or circumstances may not occur. Additional risks and uncertainties that we do not presently know about or that we currently consider to be immaterial may also affect our business operations or financial results.
Notes
(1)
See page 15 for a Reconciliation of Selected Income Statement Information to Adjusted Results for the three months ending April 27, 2025, and April 28, 2024.
(2)
See page 17 for a Summary of Restructuring Expense for the three months ending April 27, 2025, and April 28, 2024.
Expand
CULP, INC.
CONSOLIDATED STATEMENTS OF NET LOSS
FOR THE TWELVE MONTHS ENDED APRIL 27, 2025, AND APRIL 28, 2024
Unaudited
(Amounts in Thousands, Except for Per Share Data)
TWELVE MONTHS ENDED
Amount
Percent of Sales
(1)
(1)
April 27,
April 28,
% Over
April 27,
April 28,
2025
2024
(Under)
2025
2024
Net sales
$
213,237
$
225,333
(5.4
)%
100.0
%
100.0
%
Cost of sales (1)
(188,170
)
(197,394
)
(4.7
)%
88.2
%
87.6
%
Gross profit
25,067
27,939
(10.3
)%
11.8
%
12.4
%
Selling, general and administrative expenses
(35,705
)
(38,611
)
(7.5
)%
16.7
%
17.1
%
Restructuring expense (2)
(7,739
)
(636
)
N.M.
3.6
%
0.3
%
Loss from operations
(18,377
)
(11,308
)
62.5
%
(8.6
)%
(5.0
)%
Interest expense
(231
)
(11
)
N.M.
0.1
%
0.0
%
Interest income
915
1,174
(22.1
)%
0.4
%
0.5
%
Other expense
(1,018
)
(625
)
62.9
%
0.5
%
0.3
%
Loss before income taxes
(18,711
)
(10,770
)
73.7
%
(8.8
)%
(4.8
)%
Income tax expense (3)
(392
)
(3,049
)
(87.1
)%
(2.1
)%
(28.3
)%
Net loss
$
(19,103
)
$
(13,819
)
38.2
%
(9.0
)%
(6.1
)%
Net loss per share - basic
$
(1.53
)
$
(1.11
)
37.8
%
Net loss per share - diluted
$
(1.53
)
$
(1.11
)
37.8
%
Average shares outstanding-basic
12,525
12,432
0.7
%
Average shares outstanding-diluted
12,525
12,432
0.7
%
Expand
Notes
(1)
See page 16 for a Reconciliation of Selected Income Statement Information to Adjusted Results for the twelve months ending April 27, 2025, and April 28, 2024.
(2)
See page 18 for a Summary of Restructuring Expense for the twelve months ending April 27, 2025, and April 28, 2024.
(3)
Percent of sales column for income tax expense is calculated as a percent of loss before income taxes.
Expand
APRIL 27, 2025, AND APRIL 28, 2024
Unaudited
(Amounts in Thousands)
Amounts
(Condensed)
(Condensed)
April 27,
April 28,
Increase (Decrease)
2025
2024*
Dollars
Percent
Current assets
Cash and cash equivalents
$
5,629
$
10,012
(4,383
)
(43.8
)%
Short-term investments - rabbi trust
1,325
903
422
46.7
%
Accounts receivable, net
21,844
21,138
706
3.3
%
Inventories
49,309
44,843
4,466
10.0
%
Short-term notes receivable
280
264
16
6.1
%
Current income taxes receivable
—
350
(350
)
(100.0
)%
Assets held for sale
2,177
—
2,177
100.0
%
Other current assets
2,970
3,371
(401
)
(11.9
)%
Total current assets
83,534
80,881
2,653
3.3
%
Property, plant & equipment, net
24,836
33,182
(8,346
)
(25.2
)%
Right of use assets
5,908
6,203
(295
)
(4.8
)%
Intangible assets
960
1,876
(916
)
(48.8
)%
Long-term investments - rabbi trust
5,722
7,102
(1,380
)
(19.4
)%
Long-term notes receivable
1,182
1,462
(280
)
(19.2
)%
Deferred income taxes
637
518
119
23.0
%
Other assets
591
830
(239
)
(28.8
)%
Total assets
$
123,370
$
132,054
(8,684
)
(6.6
)%
Current liabilities
Lines of credit - current
8,114
—
8,114
100.0
%
Accounts payable - trade
27,323
25,607
1,716
6.7
%
Accounts payable - capital expenditures
23
343
(320
)
(93.3
)%
Operating lease liability - current
2,394
2,061
333
16.2
%
Deferred compensation - current
1,325
903
422
46.7
%
Deferred revenue
422
1,495
(1,073
)
(71.8
)%
Accrued expenses
5,333
6,726
(1,393
)
(20.7
)%
Accrued restructuring
610
—
610
100.0
%
Income taxes payable - current
1,420
972
448
46.1
%
Total current liabilities
46,964
38,107
8,857
23.2
%
Lines of credit - long-term
4,600
—
4,600
100.0
%
Operating lease liability - long-term
2,535
2,422
113
4.7
%
Income taxes payable - long-term
790
2,088
(1,298
)
(62.2
)%
Deferred income taxes
5,155
6,379
(1,224
)
(19.2
)%
Deferred compensation - long-term
5,686
6,929
(1,243
)
(17.9
)%
Total liabilities
65,730
55,925
9,805
17.5
%
Shareholders' equity
57,640
76,129
(18,489
)
(24.3
)%
Total liabilities and shareholders' equity
$
123,370
$
132,054
(8,684
)
(6.6
)%
Shares outstanding
12,559
12,470
89
0.7
%
* Derived from audited financial statements.
Expand
CULP, INC.
SUMMARY OF CASH AND DEBT
APRIL 27, 2025, AND APRIL 28, 2024
Unaudited
(Amounts in Thousands)
Amounts
April 27,
April 28,
2025
2024*
Cash:
Cash and cash equivalents
$
5,629
$
10,012
Less Debt:
Lines of credit - current
8,114
—
Lines of credit - long-term
4,600
—
Net (debt) cash position
$
(7,085
)
$
10,012
* Derived from audited financial statements.
Expand
CULP, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE TWELVE MONTHS ENDED APRIL 27, 2025, AND APRIL 28, 2024
Unaudited
(Amounts in Thousands)
TWELVE MONTHS ENDED
Amounts
April 27,
April 28,
2025
2024*
Cash flows from operating activities:
Net loss
$
(19,103
)
$
(13,819
)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
5,440
6,521
Non-cash inventory credit
(2,423
)
(1,628
)
Amortization
405
390
Stock-based compensation
650
915
Deferred income taxes
(1,343
)
387
Gain on sale of equipment
(27
)
(299
)
Non-cash restructuring expense
2,708
330
Foreign currency exchange gain
(145
)
(593
)
Changes in assets and liabilities:
Accounts receivable
(722
)
3,559
Inventories
(2,059
)
1,593
Other current assets
384
(329
)
Other assets
114
(115
)
Accounts payable - trade
1,852
(2,926
)
Deferred revenue
(1,073
)
303
Accrued restructuring
633
—
Accrued expenses and deferred compensation
(2,456
)
(1,870
)
Income taxes
(485
)
(643
)
Net cash used in operating activities
(17,650
)
(8,224
)
Cash flows from investing activities:
Capital expenditures
(2,947
)
(3,711
)
Proceeds from the sale of property, plant and equipment
1,945
385
Proceeds from note receivable
610
330
Proceeds from the sale of investments (rabbi trust)
1,725
1,449
Purchase of investments (rabbi trust)
(735
)
(884
)
Net cash provided by (used in) investing activities
598
(2,431
)
Cash flows from financing activities:
Proceeds from lines of credit
21,648
4,166
Payments on lines of credit
(8,907
)
(4,146
)
Common stock surrendered for withholding taxes payable
(68
)
(146
)
Net cash provided by (used in) financing activities
12,673
(126
)
Effect of foreign currency exchange rate changes on cash and cash equivalents
(4
)
(171
)
Decrease in cash and cash equivalents
(4,383
)
(10,952
)
Cash and cash equivalents at beginning of year
10,012
20,964
Cash and cash equivalents at end of year
$
5,629
$
10,012
Free Cash Flow (1)
$
(17,056
)
$
(10,826
)
(1) See next page for Reconciliation of Free Cash Flow for the twelve months ending April 27, 2025, and April 28, 2024.
Expand
CULP, INC.
FOR THE TWELVE MONTHS ENDED APRIL 27, 2025, AND APRIL 28, 2024
Unaudited
(Amounts in Thousands)
TWELVE MONTHS ENDED
Amounts
April 27,
April 28,
2025
2024
A) Net cash used in operating activities
$
(17,650
)
$
(8,224
)
B) Minus: Capital expenditures
(2,947
)
(3,711
)
C) Plus: Proceeds from the sale of buildings and equipment
1,945
385
D) Plus: Proceeds from note receivable
610
330
E) Plus: Proceeds from the sale of investments (rabbi trust)
1,725
1,449
F) Minus: Purchase of investments (rabbi trust)
(735
)
(884
)
G) Effects of foreign currency exchange rate changes on cash and cash equivalents
(4
)
(171
)
Free Cash Flow
$
(17,056
)
$
(10,826
)
Expand
CULP, INC.
STATEMENTS OF OPERATIONS BY SEGMENT
Unaudited
(Amounts in Thousands)
THREE MONTHS ENDED
April 27,
April 28,
% Over
April 27,
April 28,
Net Sales by Segment
2025
2024
(Under)
2025
2024
Mattress Fabrics
$
27,114
$
25,750
5.3
%
55.6
%
52.0
%
Upholstery Fabrics
21,659
23,778
(8.9
)%
44.4
%
48.0
%
Net Sales
$
48,773
$
49,528
(1.5
)%
100.0
%
100.0
%
Gross Profit by Segment
Gross Margin
Mattress Fabrics
$
3,075
$
292
N.M.
11.3
%
1.1
%
Upholstery Fabrics
4,691
4,909
(4.4
)%
21.7
%
20.6
%
Total Segment Gross Profit
7,766
5,201
49.3
%
15.9
%
10.5
%
Restructuring Related Charge (1)
(113
)
—
100.0
%
(0.2
)%
—
Gross Profit
$
7,653
$
5,201
47.1
%
15.7
%
10.5
%
Selling, General and Administrative Expenses by Segment
Percent of Sales
Mattress Fabrics
$
3,292
$
3,221
2.2
%
12.1
%
12.5
%
Upholstery Fabrics
3,638
3,934
(7.5
)%
16.8
%
16.5
%
Unallocated Corporate Expenses
1,540
2,090
(26.3
)%
3.2
%
4.2
%
Selling, General and Administrative Expenses
$
8,470
$
9,245
(8.4
)%
17.4
%
18.7
%
(Loss) Income from Operations by Segment
Operating Margin
Mattress Fabrics
$
(217
)
$
(2,929
)
(92.6
)%
(0.8
)%
(11.4
)%
Upholstery Fabrics
$
1,053
$
975
8.0
%
4.9
%
4.1
%
Unallocated Corporate Expenses
$
(1,540
)
$
(2,090
)
(26.3
)%
(3.2
)%
(4.2
)%
Total Segment Loss from Operations
(704
)
(4,044
)
(82.6
)%
(1.4
)%
(8.2
)%
Restructuring Related Charge (1)
(113
)
—
100.0
%
(0.2
)%
—
Restructuring Expense (2)
(1,422
)
(204
)
N.M.
(2.9
)%
(0.4
)%
Loss from Operations
$
(2,239
)
$
(4,248
)
(47.3
)%
(4.6
)%
(8.6
)%
Depreciation Expense by Segment
Mattress Fabrics
$
1,015
$
1,461
(30.5
)%
Upholstery Fabrics
137
162
(15.4
)%
Depreciation Expense
$
1,152
$
1,623
(29.0
)%
Expand
Notes
(1)
See page 15 for a Reconciliation of Selected Income Statement Information to Adjusted Results for the three months ending April 27, 2025, and April 28, 2024.
(2)
See page 17 for a Summary of Restructuring Expense for the three months ending April 27, 2025, and April 28, 2024.
Expand
CULP, INC.
STATEMENTS OF OPERATIONS BY SEGMENT
FOR THE TWELVE MONTHS ENDED APRIL 27, 2025, AND APRIL 28, 2024
Unaudited
(Amounts in Thousands)
TWELVE MONTHS ENDED
Amounts
Percent of Total Sales
April 27,
April 28,
% Over
April 27,
April 28,
Net Sales by Segment
2025
2024
(Under)
2025
2024
Mattress Fabrics
$
113,906
$
116,370
(2.1
)%
53.4
%
51.6
%
Upholstery Fabrics
99,331
108,963
(8.8
)%
46.6
%
48.4
%
Net Sales
$
213,237
$
225,333
(5.4
)%
100.0
%
100.0
%
Gross Profit by Segment
Gross Margin
Mattress Fabrics
$
7,936
$
6,289
26.2
%
7.0
%
5.4
%
Upholstery Fabrics
18,752
21,690
(13.5
)%
18.9
%
19.9
%
Total Segment Gross Profit
26,688
27,979
(4.6
)%
12.5
%
12.4
%
Restructuring Related Charge (1)
(1,621
)
(40
)
N.M.
(0.8
)%
(0.0
)%
Gross Profit
$
25,067
$
27,939
(10.3
)%
11.8
%
12.4
%
Selling, General and Administrative Expenses by Segment
Percent of Sales
Mattress Fabrics
$
13,171
$
13,134
0.3
%
11.6
%
11.3
%
Upholstery Fabrics
14,695
15,903
(7.6
)%
14.8
%
14.6
%
Unallocated Corporate Expenses
7,839
9,574
(18.1
)%
3.7
%
4.2
%
Selling, General and Administrative Expenses
$
35,705
$
38,611
(7.5
)%
16.7
%
17.1
%
(Loss) Income from Operations by Segment
Operating Margin
Mattress Fabrics
$
(5,235
)
$
(6,845
)
(23.5
)%
(4.6
)%
(5.9
)%
Upholstery Fabrics
$
4,057
5,787
(29.9
)%
4.1
%
5.3
%
Unallocated Corporate Expenses
$
(7,839
)
(9,574
)
(18.1
)%
(3.7
)%
(4.2
)%
Total Segment Loss from Operations
(9,017
)
(10,632
)
(15.2
)%
(4.2
)%
(4.7
)%
Restructuring Related Charge (1)
(1,621
)
(40
)
N.M.
(0.8
)%
(0.0
)%
Restructuring Expense (2)
(7,739
)
(636
)
N.M.
(3.6
)%
(0.3
)%
Loss from Operations
$
(18,377
)
$
(11,308
)
62.5
%
(8.6
)%
(5.0
)%
Return on Capital Employed (ttm) (3)
Mattress Fabrics
(9.5
)%
(10.8
)%
(12.0
)%
Upholstery Fabrics
40.5
%
62.5
%
(35.2
)%
Unallocated Corporate
N.M.
N.M.
N.M.
Consolidated
(13.0
)%
(13.9
)%
(6.5
)%
Capital Employed (3)
Mattress Fabrics
$
52,331
$
62,257
(15.9
)%
Upholstery Fabrics
16,751
7,259
130.8
%
Unallocated Corporate
2,945
4,999
(41.1
)%
Consolidated
$
72,027
$
74,515
(3.3
)%
Depreciation Expense by Segment
Mattress Fabrics (4)
$
6,178
$
5,883
5.0
%
Upholstery Fabrics
601
638
(5.8
)%
Depreciation Expense
$
6,779
$
6,521
4.0
%
Expand
Notes
(1)
See page 16 for a Reconciliation of Selected Income Statement Information to Adjusted Results for the twelve months ending April 27, 2025, and April 28, 2024.
(2)
See page 18 for a Summary of Restructuring Expense for the twelve months ending April 27, 2025, and April 28, 2024.
(3)
See pages 20 through 23 for calculation of Return on Capital Employed by Segment for the trailing twelve months ending April 27, 2025, and April 28, 2024, and a reconciliation to information from our U.S. GAAP financial statements. The capital employed balances are as of April 27, 2025, and April 28, 2024.
(4)
During the twelve-month period ending April 27, 2025, depreciation expense for the mattress fabrics segment included additional depreciation expense related to the shortening of useful lives of equipment associated with the closure of operations at our manufacturing facility located in Quebec, Canada. The amount of additional depreciation expense totaling $1.3 million was classified as restructuring expense in our fiscal 2025 Consolidated Statements of Net Loss.
Expand
FOR THE THREE MONTHS ENDED APRIL 27, 2025, AND APRIL 28, 2024
Unaudited
(Amounts in Thousands)
As Reported
Adjusted Results
April 27,
April 27,
2025
Adjustments
2025
Net sales
$
48,773
—
$
48,773
Cost of sales (1)
(41,120
)
113
(41,007
)
Gross profit
7,653
113
7,766
Selling, general and administrative expenses
(8,470
)
—
(8,470
)
Restructuring expense (2)
(1,422
)
1,422
—
Loss from operations
$
(2,239
)
1,535
$
(704
)
Expand
Notes
(1)
During the three months ending April 27, 2025, cost of sales included a restructuring related charge of $113,000 for losses on the disposal of inventory related to the closure of operations at the company's manufacturing facility located in Quebec, Canada.
(2)
See page 17 for a Summary of Restructuring Expense for the three months ending April 27, 2025.
Expand
As Reported
Adjusted Results
April 28,
April 28,
2024
Adjustments
2024
Net sales
$
49,528
—
$
49,528
Cost of sales
(44,327
)
—
(44,327
)
Gross profit
5,201
—
5,201
Selling, general and administrative expenses
(9,245
)
—
(9,245
)
Restructuring expense (1)
(204
)
204
—
Loss from operations
$
(4,248
)
204
$
(4,044
)
Expand
Notes
(1)
See page 17 for a Summary of Restructuring Expense for the three months ending April 28, 2024.
Expand
CULP, INC.
Unaudited
(Amounts in Thousands)
As Reported
Adjusted Results
April 27,
April 27,
2025
Adjustments
2025
Net sales
$
213,237
—
$
213,237
Cost of sales (1)
(188,170
)
1,621
(186,549
)
Gross profit
25,067
1,621
26,688
Selling, general and administrative expenses
(35,705
)
—
(35,705
)
Restructuring expense (2)
(7,739
)
7,739
—
Loss from operations
$
(18,377
)
9,360
$
(9,017
)
Expand
Notes
(1)
During the twelve months ending April 27, 2025, cost of sales included a restructuring related charge of $1.6 million for losses on the disposal, valuation, and markdowns of inventory related to the closure of the company's manufacturing facility located in Quebec, Canada.
(2)
See page 18 for a Summary of Restructuring Expense for the twelve months ending April 27, 2025.
Expand
As Reported
Adjusted Results
April 28,
April 28,
2024
Adjustments
2024
Net sales
$
225,333
—
$
225,333
Cost of sales (1)
(197,394
)
40
(197,354
)
Gross profit
27,939
40
27,979
Selling, general and administrative expenses
(38,611
)
—
(38,611
)
Restructuring expense (2)
(636
)
636
—
Loss from operations
$
(11,308
)
676
$
(10,632
)
Expand
Notes
(1)
During the twelve months ending April 27, 2024, cost of sales included a restructuring related charge of $40,000 for markdowns of inventory related to the discontinuance of production of cut and sewn upholstery kits at the company's facility in Ouanaminthe, Haiti.
(2)
See page 18 for a Summary of Restructuring Expense for the twelve months ending April 28, 2024.
Expand
CULP, INC.
SUMMARY OF RESTRUCTURING EXPENSE
FOR THE THREE MONTHS ENDED APRIL 27, 2025, AND APRIL 28, 2024
Unaudited
(Amounts in Thousands)
The following summarizes restructuring expense for three-month period ending April 27, 2025:
Upholstery
Mattress
Unallocated
Description
Fabrics
Fabrics
Corporate
Total
Employee termination benefits
$
112
$
12
$
—
$
124
Impairment charge related to intangible asset
—
—
540
540
Loss on the sale and disposal of equipment
24
2
—
26
Facility consolidation and relocation expenses
—
322
—
322
Cost incurred to ready a closed facility for sale
—
360
—
360
Other associated costs
—
50
—
50
Total restructuring expense (1)
$
136
$
746
$
540
$
1,422
Expand
(1)
During the three months ending April 27, 2025, restructuring expense of $1.4 million represents costs associated with (i) the closure of the company's mattress fabrics manufacturing facility located in Quebec, Canada; (ii) initial costs related to consolidating production and distribution activities from the company's upholstery fabrics distribution center located in Burlington, N.C. to the company's mattress fabrics manufacturing and distribution center located in Stokesdale, N.C.; and (iii) other expenses incurred as part of the company's strategic plan to transform its operating model as announced on April 24, 2025.
Expand
The following summarizes restructuring expense for three-month period ending April 28, 2024:
Upholstery
Description
Fabrics
Employee termination benefits
204
Total restructuring expense (1)
$
204
Expand
(1)
During the three months ending April 28, 2024, restructuring expense of $204,000 represents employee termination benefits associated with the rationalization of the upholstery fabrics finishing operation located in Shanghai, China.
Expand
CULP, INC.
SUMMARY OF RESTRUCTURING EXPENSE
FOR THE TWELVE MONTHS ENDED APRIL 27, 2025, AND APRIL 28, 2024
Unaudited
(Amounts in Thousands)
The following summarizes restructuring expense for twelve-month period ending April 27, 2025:
Upholstery
Mattress
Unallocated
Description
Fabrics
Fabrics
Corporate
Total
Employee termination benefits
$
214
$
1,338
$
—
$
1,552
Impairment charge related to intangible asset
$
—
$
—
$
540
$
540
Accelerated depreciation
—
1,339
—
1,339
Impairment charges related to fixed assets
—
131
—
131
Loss (gain) on the sale of equipment
24
(171
)
—
(147
)
Lease termination costs
—
849
—
849
Facility consolidation and relocation expenses
53
2,384
—
2,437
Cost incurred to ready a closed facility for sale
—
788
—
788
Other associated costs
14
236
—
250
Total restructuring expense (1)
$
305
$
6,894
$
540
$
7,739
Expand
(1)
During the twelve months ending April 27, 2025, restructuring expense of $7.7 million represents costs associated with (i) consolidating the company's North American mattress fabrics operations, including the closure of the company's mattress fabrics manufacturing facility located in Quebec, Canada; (ii) consolidating two leased facilities related to the sewn mattress cover operation located in Ouanaminthe, Haiti, into one facility and reducing other operating expenses at this location; (iii) initial costs related to consolidating production and distribution activities from the upholstery fabrics distribution center located in Burlington, N.C. to the mattress fabrics manufacturing and distribution center located in Stokesdale, N.C.; and (v) other expenses incurred as part of the company's strategic plan to transform its operating model as announced on April 24, 2025.
Expand
(1)
During the twelve months ending April 28, 2024, restructuring expense of $636,000 represents impairment charges related to equipment of $329,000 and employee termination benefits of $103,000 related to the discontinuance of production of cut and sewn upholstery kits at the company's facility located in Ouanaminthe, Haiti and employee termination benefits of $204,000 related to the rationalization of the upholstery fabrics finishing operation located in Shanghai, China.
Expand
CULP, INC.
FOR THE TWELVE MONTHS ENDED APRIL 27, 2025
Unaudited
(Amounts in Thousands)
Adjusted Operating
(Loss) Income
Twelve Months
Ended
Average
Capital
Return on
Avg. Capital
April 27, 2025
Employed (1)
Employed (2)
Mattress Fabrics
$
(5,235
)
$
55,170
(9.5
)%
Upholstery Fabrics
4,057
10,027
40.5
%
Unallocated Corporate
(7,839
)
4,427
N.M.
Consolidated
$
(9,017
)
$
69,624
(13.0
)%
Average Capital Employed
As of the Three Months Ended April 27, 2025
As of the Three Months Ended January 26, 2025
As of the Three Months Ended October 27, 2024
Mattress
Upholstery
Unallocated
Mattress
Upholstery
Unallocated
Mattress
Upholstery
Unallocated
Fabrics
Fabrics
Corporate
Total
Fabrics
Fabrics
Corporate
Total
Fabrics
Fabrics
Corporate
Total
Total assets (3)
$
70,825
$
32,082
$
20,463
$
123,370
$
70,877
$
33,697
$
22,981
$
127,555
$
69,261
$
31,385
$
28,341
$
128,987
Total liabilities
(18,494
)
(15,331
)
(31,905
)
(65,730
)
(20,337
)
(21,081
)
(26,487
)
(67,905
)
(14,948
)
(24,783
)
(25,633
)
(65,364
)
Subtotal
$
52,331
$
16,751
$
(11,442
)
$
57,640
$
50,540
$
12,616
$
(3,506
)
$
59,650
$
54,313
$
6,602
$
2,708
$
63,623
Cash and cash equivalents
—
—
(5,629
)
(5,629
)
—
—
(5,279
)
(5,279
)
—
—
(10,531
)
(10,531
)
Short-term investments - Rabbi Trust
—
—
(1,325
)
(1,325
)
—
—
(1,753
)
(1,753
)
—
—
(919
)
(919
)
Current income taxes receivable
—
—
—
—
—
—
(1,137
)
(1,137
)
—
—
(979
)
(979
)
Long-term investments - Rabbi Trust
—
—
(5,722
)
(5,722
)
—
—
(6,250
)
(6,250
)
—
—
(7,105
)
(7,105
)
Deferred income taxes - non-current
—
—
(637
)
(637
)
—
—
(490
)
(490
)
—
—
(559
)
(559
)
Lines of credit - current
—
—
8,114
8,114
—
—
5,384
5,384
—
—
4,074
4,074
Deferred compensation - current
—
—
1,325
1,325
—
—
1,753
1,753
—
—
919
919
Accrued restructuring
610
610
723
723
863
863
Income taxes payable - current
—
—
1,420
1,420
—
—
828
828
—
—
1,165
1,165
Lines of credit - long-term
4,600
4,600
Income taxes payable - long-term
—
—
790
790
—
—
1,400
1,400
—
—
1,378
1,378
Deferred income taxes - non-current
—
—
5,155
5,155
—
—
6,582
6,582
—
—
6,624
6,624
Deferred compensation - long-term
—
—
5,686
5,686
—
—
6,151
6,151
—
—
6,975
6,975
Total Capital Employed
$
52,331
$
16,751
$
2,945
$
72,027
$
50,540
$
12,616
$
4,406
$
67,562
$
54,313
$
6,602
$
4,613
$
65,528
Expand
CULP, INC.
RETURN ON CAPITAL EMPLOYED BY SEGMENT - CONTINUED
FOR THE TWELVE MONTHS ENDED APRIL 27, 2025
Unaudited
(Amounts in Thousands)
As of the Three Months Ended July 28, 2024
As of the Three Months Ended April 28, 2024
Mattress
Upholstery
Unallocated
Mattress
Upholstery
Unallocated
Fabrics
Fabrics
Corporate
Total
Fabrics
Fabrics
Corporate
Total
Total assets (3)
$
66,713
$
31,763
$
30,663
$
129,139
$
72,060
$
32,629
$
27,365
$
132,054
Total liabilities
(10,303
)
(24,857
)
(24,855
)
(60,015
)
(9,803
)
(25,370
)
(20,752
)
(55,925
)
Subtotal
$
56,410
$
6,906
$
5,808
$
69,124
$
62,257
$
7,259
$
6,613
$
76,129
Cash and cash equivalents
—
—
(13,472
)
(13,472
)
—
—
(10,012
)
(10,012
)
Short-term investments - Rabbi Trust
—
—
(954
)
(954
)
—
—
(903
)
(903
)
Current income taxes receivable
—
—
(532
)
(532
)
—
—
(350
)
(350
)
Long-term investments - Rabbi Trust
—
—
(7,089
)
(7,089
)
—
—
(7,102
)
(7,102
)
Deferred income taxes - non-current
—
—
(528
)
(528
)
—
—
(518
)
(518
)
Lines of credit
—
—
4,017
4,017
—
—
—
—
Deferred compensation - current
—
—
954
954
—
—
903
903
Accrued Restructuring
633
633
—
—
—
—
Income taxes payable - current
—
—
759
759
—
—
972
972
Income taxes payable - long-term
—
—
2,180
2,180
—
—
2,088
2,088
Deferred income taxes - non-current
—
—
6,449
6,449
—
—
6,379
6,379
Deferred compensation - long-term
—
—
6,946
6,946
—
—
6,929
6,929
Total Capital Employed
$
56,410
$
6,906
$
5,171
$
68,487
$
62,257
$
7,259
$
4,999
$
74,515
Mattress
Upholstery
Unallocated
Fabrics
Fabrics
Corporate
Consolidated
Average Capital Employed (2)
$
55,170
$
10,027
$
4,427
$
69,624
Expand
Notes
(1)
Average capital employed is calculated independently for each segment and on a consolidated basis using the five quarterly periods ending April 27, 2025, January 26, 2025, October 27, 2024, July 28, 2024, and April 28, 2024.
(2)
Return on average capital employed represents the twelve months adjusted operating (loss) income as of April 27, 2025, divided by average capital employed. Average capital employed does not include cash and cash equivalents, short-term and long-term investments – rabbi trust, income taxes receivable and payable, accrued restructuring, current and long-term lines of credit, non-current deferred income tax assets and liabilities, and current and non-current deferred compensation.
(3)
Intangible assets are included in unallocated corporate for all periods presented and therefore, have no effect on capital employed and return on capital employed for our mattress fabrics and upholstery fabrics segments.
Expand
CULP INC.
RETURN ON CAPITAL EMPLOYED BY SEGMENT
FOR THE TWELVE MONTHS ENDED April 28, 2024
Unaudited
(Amounts in Thousands)
Adjusted Operating
(Loss) Income
Twelve Months
Ended
Average
Capital
Return on
Avg. Capital
April 28, 2024
Employed (1)
Employed (2)
Mattress Fabrics
$
(6,845
)
$
63,189
(10.8
)%
Upholstery Fabrics
5,787
9,263
62.5
%
Unallocated Corporate
(9,574
)
3,784
N.M.
Consolidated
$
(10,632
)
$
76,235
(13.9
)%
Average Capital Employed
As of the Three months ended April 28, 2024
As of the Three months ended January 28, 2024
As of the Three months ended October 29, 2023
Mattress
Upholstery
Unallocated
Mattress
Upholstery
Unallocated
Mattress
Upholstery
Unallocated
Fabrics
Fabrics
Corporate
Total
Fabrics
Fabrics
Corporate
Total
Fabrics
Fabrics
Corporate
Total
Total assets (3)
$
72,060
$
32,629
$
27,365
$
132,054
$
75,572
$
38,085
$
28,341
$
141,998
$
75,924
$
35,082
$
31,154
$
142,160
Total liabilities
(9,803
)
(25,370
)
(20,752
)
(55,925
)
(8,234
)
(32,201
)
(20,767
)
(61,202
)
(14,739
)
(23,758
)
(20,035
)
(58,532
)
Subtotal
$
62,257
$
7,259
$
6,613
$
76,129
$
67,338
$
5,884
$
7,574
$
80,796
$
61,185
$
11,324
$
11,119
$
83,628
Cash and cash equivalents
—
—
(10,012
)
(10,012
)
—
—
(12,585
)
(12,585
)
—
—
(15,214
)
(15,214
)
Short-term investments - Rabbi Trust
—
—
(903
)
(903
)
—
—
(937
)
(937
)
—
—
(937
)
(937
)
Current income taxes receivable
—
—
(350
)
(350
)
—
—
(476
)
(476
)
—
—
(340
)
(340
)
Long-term investments - Rabbi Trust
—
—
(7,102
)
(7,102
)
—
—
(7,083
)
(7,083
)
—
—
(6,995
)
(6,995
)
Deferred income taxes - non-current
—
—
(518
)
(518
)
—
—
(531
)
(531
)
—
—
(472
)
(472
)
Deferred compensation - current
—
—
903
903
—
—
937
937
—
—
937
937
Income taxes payable - current
—
—
972
972
—
—
1,070
1,070
—
—
998
998
Income taxes payable - long-term
—
—
2,088
2,088
—
—
2,072
2,072
—
—
2,055
2,055
Deferred income taxes - non-current
—
—
6,379
6,379
—
—
6,177
6,177
—
—
5,663
5,663
Deferred compensation - long-term
—
—
6,929
6,929
—
—
6,856
6,856
—
—
6,748
6,748
Total Capital Employed
$
62,257
$
7,259
$
4,999
$
74,515
$
67,338
$
5,884
$
3,074
$
76,296
$
61,185
$
11,324
$
3,562
$
76,071
Expand
CULP INC.
RETURN ON CAPITAL EMPLOYED BY SEGMENT - CONTINUED
FOR THE TWELVE MONTHS ENDED APRIL 28, 2024
Unaudited
(Amounts in Thousands)
As of the Three Months Ended July 30, 2023
As of the Three Months Ended April 30, 2023
Mattress
Upholstery
Unallocated
Mattress
Upholstery
Unallocated
Fabrics
Fabrics
Corporate
Total
Fabrics
Fabrics
Corporate
Total
Total assets (3)
$
72,286
$
37,592
$
33,024
$
142,902
$
75,494
$
39,127

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
43 minutes ago
- Business Wire
SabbaticalHomes Celebrates 25 Years of Housing Minds on the Move
LOS ANGELES--(BUSINESS WIRE)--SabbaticalHomes celebrates its 25th anniversary in 2025. With more than 2 million members in 65 countries, the international housing platform has long been the trusted resource for academics and scholars seeking temporary accommodations worldwide. As higher education faces global uncertainty and housing costs continue to climb, SabbaticalHomes is more relevant than ever. A Home for Scholars Founded in 2000 by Nadege Conger, SabbaticalHomes was inspired by personal experience. As part of an academic family, Conger witnessed how difficult it was for scholars to find suitable housing while working abroad. Seeing the potential of the internet to connect like-minded people, she coded the first version of the site herself—long before the plethora of short-term rental platforms emerged. Despite international disruptions like 9/11, economic downturns, and COVID-19, the company remains focused on its mission: supporting those who advance knowledge through research, writing, and education. About the Founder Originally from France and now based in Southern California, Conger earned her MBA from McGill University in Montreal after studying in France and Canada. Her early career included roles at Disney Paris and Deloitte & Touche, but she sought a more meaningful path. 'I'm particularly proud that SabbaticalHomes has grown organically, driven by purpose rather than venture capital,' said Conger. 'Each listing is more than a home—it's a vessel for thinkers, helping them contribute to society. We prioritize trust and respect over profits.' A Global Academic Community SabbaticalHomes connects professors, postdocs, teachers, graduate students, and university staff as well as writers, scientists, artists, journalists, filmmakers, and doctors—people who value lifelong learning and intellectual exchange. Its members include Nobel laureates, Fulbright scholars, and fellowship recipients worldwide. Many return year after year, sharing testimonials that reflect the platform's deep impact and community-first approach. How It Works Members list homes for rent or exchange with house-sitting and sharing options. They arrange details independently and directly—checking references, drafting contracts, and handling payments. This model encourages trust, flexibility, and authentic personal connections. With flat listing and match fees, SabbaticalHomes serves users at all career stages. Looking Ahead As it marks 25 years, SabbaticalHomes continues to support 'Minds on the Move.' With a strong foundation and a loyal community, the platform is well-positioned to empower scholars and thought leaders for decades to come. For more information, visit
Yahoo
an hour ago
- Yahoo
SF Holding Launched H-share Equity Issuance and Concurrent Zero Coupon Convertible Bonds Offering
HONG KONG, June 26, 2025 /PRNewswire/ -- S.F. Holding Co., Ltd. ( 'SF Holding', 'SF' or the 'the Company') announced a USD 376 million H-share equity placement and concurrent USD 376 million offering of 363-day zero-coupon convertible bonds. Apart from improving the liquidity of H-shares for a broader base of investors, the Company intends to use the net proceeds from the transactions for strengthening its international and cross-border logistics capabilities, research and development of advanced technologies and digital solutions, enhancing its capital structure and general corporate purposes. Terms of the Equity Placement The equity placement comprises the issuance of 70,000,000 new H-shares at a placing price of HKD 42.15 per share, representing a 8.8% discount to the closing price on the Hong Kong Stock Exchange as of June 25, 2025. The equity placement will raise approximately USD 376 million in gross proceeds. Terms of the Convertible Bond Offering The convertible bonds will be issued by SF Holding Investment 2023 Limited, a wholly owned subsidiary of the Company incorporated in the British Virgin Islands. The Company will unconditionally and irrevocably guarantee the due payment of all sums expressed to be payable by the issuer under the convertible bonds. The convertible bonds to be issued are zero-coupon instruments with a maturity of 363 days, and a yield to maturity of 0.5% per annum. The initial conversion price will be HKD 48.47, representing a 15% premium over the placing price in the equity placement. Bondholders may convert all or part of their holdings into H-shares at the prevailing conversion price, at any time from (and including) the 41st day after the issue date and up to the close of business on the date falling 10 working days prior to the maturity date. Strategic Outlook The transaction is SF's first offshore issuance since its landmark 2024 Hong Kong IPO, providing investors with flexible capital in a dynamic market environment. The combined equity and short-duration convertible bond structure reflects financial discipline, considering not only enhancing liquidity but also mitigating shareholder dilution risks by the structuring of conversion terms. SF is the largest integrated logistics service provider in Asia and the fourth largest globally. Under its "The One in Asia" strategy, the Company is accelerating its global footprint through strategic network expansion and continuous upgrades to its services and solutions. It has positioned international markets as its second growth engine. In 2024, revenue from SF's supply chain and international businesses grew by 17.5% year-on-year. About SF Holding Founded in 1993, S.F. Holding Co., Ltd. ( is the largest integrated logistics service provider in Asia and the fourth largest globally. Listed on the Shenzhen Stock Exchange and the Hong Kong Stock Exchange, SF Holding is the constituent stock in the CSI 300 Index, MSCI Emerging Market Index and FTSE China 50 Index. Demonstrating a commitment to being fast, reliable, and customer-centric, the Company possesses digital technology to promote the development of intelligent and green supply chains. For further information, please visit View original content: SOURCE S.F. Holding Co., Ltd. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China's NMPA
SHANGHAI, June 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. The NDA submission is mainly based on the results of an open-label, multicenter, randomized controlled confirmatory Phase II clinical trial (CT041-ST-01, NCT04581473) conducted in China. The data have been presented in The Lancet and at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. In addition, the company is actively expanding satri-cel application in early-line treatment and perioperative treatment of cancer, including an ongoing Phase Ib registrational trial for pancreatic cancer adjuvant treatment and an ongoing investigator-initiated trial for consolidation treatment following adjuvant therapy in patients with resected G/GEJA. Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of the CT041-ST-01 clinical trial, said, "Gastric cancer is a malignancy with a substantial global disease burden and significant treatment challenges. For patients with advanced gastric cancer, in particular, existing therapeutic options and their efficacy remain severely limited, resulting in extremely poor survival outcomes. Within the current treatment landscape for gastric cancer, a growing number of patients have experienced failure with immunotherapy and anti-angiogenic therapies. Treatment choices and potential benefits become even more constrained in the third-line setting and beyond. Consequently, there exists a significant unmet clinical need for advanced gastric cancer patients after second-line treatment failure. The confirmatory randomized controlled clinical trial of satri-cel has clearly demonstrated that, compared with existing standard therapies, satri-cel offers significant advantages and clinical value in extending both progression-free survival (PFS) and overall survival (OS). The trial results have garnered widespread international attention and recognition, providing a solid evidentiary foundation for satri-cel's New Drug Application (NDA) submission. We look forward to the approval and market launch of satri-cel, which will offer a new treatment option for the broader population of gastric cancer patients." Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are delighted to announce that the NDA for our self-developed Claudin18.2-targeted CAR T-cell product satri-cel has been accepted for review by China's NMPA. This marks the world's first CAR T-cell therapy product for solid tumors to reach the NDA stage—a major milestone for the CAR-T field. I extend my sincere gratitude to all clinical investigators, trial coordinators, and patients involved in this program. We are hopeful for its timely approval to provide gastric cancer patients with a new treatment option." About Satri-cel Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib registrational trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595). Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA for the treatment of G/GEJA in September 2020. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgenFor more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics